<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68824">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913340</url>
  </required_header>
  <id_info>
    <org_study_id>P0055603-01</org_study_id>
    <nct_id>NCT01913340</nct_id>
  </id_info>
  <brief_title>Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEAT O)</brief_title>
  <acronym>NEAT O</acronym>
  <official_title>Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiser Santa Clara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE), a condition of reduced blood and oxygen flow to a
      baby's brain near the time of birth, may cause death or neurologic disability. Cooling
      therapy (hypothermia) provides some protection, but about half of affected infants still
      have a poor outcome. This clinical trial will determine if the drug erythropoietin, given
      with hypothermia, is safe to use as a treatment that may further reduce the risk of
      neurologic deficits after HIE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I/II clinical trial is designed to demonstrate:

        1. The feasibility of recruiting, enrolling and following 50 patients with moderate to
           severe HIE at 5 sites, while meeting specified recruitment and follow-up target goals.

        2. The safety of high-dose Epo therapy in neonates with HIE with respect to systemic organ
           function and general growth parameters.

        3. The value of brain MRI/MRS performed at 4-7 days of age as a biomarker of motor
           function at 12 months of age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Markers of organ function</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected averaged of 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The investigators will monitor organ function and adverse events until hospital discharge from the neonatal intensive care unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alberta Infant Motor Score (AIMS)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The instrument contains 58 items that are broken down into 4 motor sub-scales: prone, supine, sit and stand. The assessment entails observation only with minimal handling, and is typically completed in 10-20 minutes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Warner Initial Developmental Evaluation of Adaptive and Functional Skills (WIDEA)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A 43-item questionnaire developed and standardized to assess the functional domains of self-care, motor function, communication and social cognition in young children</description>
  </other_outcome>
  <other_outcome>
    <measure>Gross Motor Function Classification Scale (GMFCS)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This is a validated and widely used tool for classifying severity of motor impairment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hypoxic-ischemic Encephalopathy</condition>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Birth Asphyxia</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>1000 U/kg/dose IV every 48 hours x 5</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Procrit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>placebo: 1 cc NS IV every 48 hours x 5</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns ≥ 36 weeks gestation, &lt; 23 hours of age at time of consent, must meet all 3
             Inclusion Criteria to be eligible for the study:

               1. Perinatal depression = at least one of the following: a) Apgar ≤5 at 10 min or
                  b) required             resuscitation (endotracheal or mask ventilation, or
                  chest compressions) at 10 min or c) pH &lt; 7.0 or base deficit ≥15 in cord,
                  arterial, or venous blood obtained at &lt;60 min of age;

               2. Moderate to severe encephalopathy = at least 3 of 6 modified Sarnat criteria
                  present between 1-6 h of birth: a) reduced level of consciousness; b) decreased
                  spontaneous activity; c) hypotonia; d) decreased suck; e) decreased Moro reflex;
                  or f) respiratory distress including periodic breathing or apnea; and

               3. Hypothermia = passive or active cooling begun by 6 hours of age.

        Exclusion Criteria:

          -  Intrauterine growth restriction (BW &lt;1800 g);

          -  Major congenital malformation; suspected genetic syndrome, metabolic disorder or
             TORCH infection;

          -  Head circumference &lt; 2 SD for gestation;

          -  Infant for whom withdrawal of supportive care is being considered; or

          -  Anticipated inability to collect primary endpoint at 12 months of age.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne W Wu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne W Wu, MD, MPH</last_name>
    <phone>415-353-3678</phone>
    <email>wuy@neuropeds.ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Knowles</last_name>
    <phone>415-514-8139</phone>
    <email>KnowlesK@peds.ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital Research Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Mulkey, MD</last_name>
      <email>MulkeySarah@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Mulkey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivian Yap, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne W Wu, MD, MPH</last_name>
      <phone>415-353-3678</phone>
      <email>wuy@neuropeds.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karin Knowles</last_name>
      <phone>415-514-8139</phone>
      <email>KnowlesK@peds.ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Roberta A Ballard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne W Wu, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taeun Chang, MD</last_name>
      <phone>202-259-0170</phone>
      <email>tchang@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Taeun Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Massaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Mathur, MD</last_name>
      <phone>314-454-4031</phone>
      <email>mathur_a@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Mathur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert McKinstry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Mayock, MD</last_name>
      <phone>206-543-5257</phone>
      <email>mayock@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis Mayock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Juul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC, Juul SE. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012 Oct;130(4):683-91. doi: 10.1542/peds.2012-0498. Epub 2012 Sep 24.</citation>
    <PMID>23008465</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <keyword>therapeutic hypothermia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
